Parallel Health World News Logo

Parallel Health World

cropper
  • Home
  • Categories
    • EcoHealth Trends
    • Healing Naturally
    • Age-Defying Diets
    • Supplement Savvy
    • Mind-Body Synergy
    • Finance and Health
    • Biolimitless
    • Tech Hacks
    • Health & Medicine
    • Political
    • BioBuzz
    • Holistic Rehabilitation Techniques
    • Practitioner Insights
    • AI In Healthcare
  • Featured Business Profiles
1 Minute Read

Biolimitless New Path To Health

Discover a New Path to Health with Dr. Eric Nepute and BioLimitless

Transcript: You know, it's been said that knowledge is power, but wisdom is taking that knowledge and applying it to your life. And without that knowledge, our people will perish. We also know that the Latin meaning of the word doctor is teacher, and your doctor's job is to teach, reach, and inspire, and motivate you to get that knowledge and wisdom and to change your life and the life of your family? And what if I told you that the majority of the things that you learned about health, about healing, about wellness was wrong or maybe even a lie?

Hi. My name is doctor Eric Napputi, and I've dedicated my life to helping people get to the root cause of their problems.

And human suffering. And I've really gone about this in a very non conventional way. Let me tell you a little bit about my background.

Ever since I was a child, I've always wanted to be a physician. I've always wanted to help people solve their problems. But when I started my conventional medical training, it just didn't answer the question, why? And that's where my outside of the box non conventional health and wellness training started.

You see, not only my primary care provider, but I also have a doctorate in natural medicine, a doctorate in chiropractic, a fellowship in functional neurology, a fellowship in internal health. I'm a certified athletic trainer. I've got a master's in clinical nutrition and three bachelor's degrees in human anatomy, sports medicine, and chemistry. And I don't tell you that to impress you, but to impress upon you that I think and act differently because of that.

Not only do I have a very diverse educational background, but my business background is very unique as well. I've owned and operated over thirty of my own health and wellness centers. They're fully integrated practices, but people would come from all over the world to be seen. I've owned and operated surgical centers across the United States.

I've been a part owner of a nutraceutical company. I've owned part of a hospital system. I've been involved with pharmaceutical, biological companies.

I've helped train thousands of doctors across the globe on how to get to the root cause of chronic illness. And as of recently, I've been honored to be a part of the Make America Healthy Again campaign where secretary of health and human services, Bobby Kennedy Junior, has asked me to be a part of the movement to help eradicate chronic illness and childhood illness across the globe. I've also testified in front of Congress at a federal and a state level to help improve policies and remove some of the unnecessary regulations so that people can actually get to the root cause of their problems and not just manage the diseases.

Over the past two decades, I've dedicated my life to understanding the human body at its most fundamental level. I've always been driven by one mission and that's to find the root cause of health issues, not just treat the symptoms. Now, let me ask you this. Have you or anyone you know ever struggled with fatigue, brain fog, weight gain, hormonal imbalances, digestive issues, leaky gut problems, chronic pain, low libido, anxiety, mood swings, autoimmune disorders, hypertension, heart disease, or liver and kidney issues. I know the list is long, but what if I told you there was a company backed by real science and real results that can help you with all of these issues and much more.

Welcome to BioLimimus.

I've seen firsthand how powerful the right approach can be and that's exactly what I want to talk to you about with BioLimimus.

Because the more you understand about how you are and how your body works, the better you can help yourself and help your family. Because self care is the real health care, and it begins with understanding about you. At Bio Limitless, we offer unique technologies backed by research and designed to help tens of thousands of people get better every single day. Let me tell you a little bit about some of the products and how they work. Let's first talk about our cellular the reset formula. Cellular the reset is not like any typical metabolic or performance supplement on the market. It's a peptide based bioregulator formula designed to work at a cellular level by combining strategic peptides in a specific manner in order to improve mitochondria, improve cellular repair, and improve metabolism.

Some of the amazing results that you're going to have with that is rapid fat loss. We're gonna shift your body from a sugar burner to a fat burner without losing muscle mass. In fact, our peptide blend has an exercise in a bottle in it where it literally mimics exercise and helps your body build muscle while burning fat at the same time and helping systemically reduce inflammation, which accelerates tissue recovery and improves endurance, helping your body rest, recharge, and operate at its full biologic potential.

Now let's talk a little bit about our cell signals formula. This is a revolutionary bioregulator formula designed to optimize cellular communication and restore cellular efficiency, supporting energy, performance and systemic balance in the human body. Listen. As we age, the production of key cell signaling molecules decline, dropping by ninety percent or more by the age of thirty.

This disrupts our cells' ability to vibrate at a frequency for energy production, detoxification, and repair. And these changes contribute to fatigue, brain fog, slower recovery, and other age related challenges. Cell signal combines bioavailable nutrients to offset those issues and help restore optimal performance of the human body. Now I'm sure many of you know that we're living in an era where anxiety, depression, insomnia, and mental illness are off the charts and rising.

Our NeuroReboot formula is a potent tripeptide bioregulator formula designed to help rewire brain function, refire metabolic processes, and reboot cellular regeneration.

This advanced blend of peptides works synergistically to restore balance at a cellular level, helping you think clearer, feel stronger, and perform at your best. This formula helps cellular renewal restoration, helps metabolic activation, cognitive function optimization.

It connects the brain gut axis, which helps maintain the communication between the neuro transmitters of your gut and your brain and it helps with cellular vitality and is the key to longevity.

Now since we're speaking of the brain gut connection, let me tell you about one of my favorite formulas, our master microbiotic formula. It is a clinically validated bioregulator formula designed to optimize gut health and recolonize the microbiome with potent spore based master microbes and is supported by gut healing regenerative peptide peptide known as BPC one five seven, the healing peptide.

Utilizing our patented phytomicroencapsulation technology, this formula delivers beneficial probiotics directly into the small intestine where we need them the most. This formula helps restore gut health, boost immune system, and enhances overall well-being in the human body.

Now in our increasingly toxic world, we are bombarded with harmful substances every single day from heavy metals to microplastics to pesticides, herbicides, larvicides, fungicides, all these chemical toxins that make us toxic. Over ninety percent of Americans have detectable levels of harmful chemicals in their body that is literally killing them. Our detox pro plus formula is built to combat this toxic burden and support natural detoxification in a safe daily usable formula scientifically backed with ingredients that bind and remove toxins while restoring balance at a cellular, genetic, and microbial level. This advanced blend also supports mitochondrial function, healthy inflammation markers, and promotes gut and liver detoxification processes. By targeting the root cause of toxic accumulation, detox pro plus helps restore energy, strengthen immune function, and revitalize overall well-being while empowering the human body to function properly.

Now unlike most healthcare experts at Bio Limitless, we test, we don't guess. Now I'm not here to discredit traditional healthcare, but if you've been searching for a better way, one that understands how your body works at a genetic and cellular level, then Bio Limitless is the answer.

At BioLimulus, we know that true health starts within you. You have the power to transform your life, but it has to start with you. Self care reimagine begins with you understanding more about yourself. Our bioliminalist DNA discovery kit measures over eight hundred thousand genetic markers in your body and gives you the map and the blueprint how to live your life.

If you don't understand how to live your genetic lifestyle, I don't care what vitamins, minerals, and supplements you take, you're not optimizing your production. What if there was a test that you could take from home that could measure how you should sleep, how you should exercise, what supplements you should have, when you should take them, what types of injuries your body's prone to, and much, much more. This test by itself has been an absolute game changer for thousands of my patients, and it'll be a game changer for you as well. At BioLimulus, we know that health starts from within.

You have the power to transform your health, but it has to start with you. So let's get started today. Go to the link below, explore the products, and join the thousands who have found a better path to health with biolimimus. Click the link, take control of your health, and transform your life because self care is the real health care.

Biolimitless Selfcare
Biolimitless

755 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
06.24.2026

Phio Pharmaceuticals PH-762: Advancing Innovation in Cancer Treatment

Update Phio Pharmaceuticals Takes a Major Step Forward with PH-762In the ever-evolving landscape of biotechnology, Phio Pharmaceuticals has marked a significant milestone with its lead candidate, PH-762. This innovative approach aims to address critical medical challenges, including cancer and immune disorders, showcasing a glimpse of the future in targeted therapies that manipulate the body's own mechanisms.Understanding the Science Behind PH-762PH-762 is designed using a unique technology known as Cell Therapy Platform (CTP), which enables the pharmaceutical to leverage the patient's immune system effectively. This particular method modifies T-cells to seek and destroy cancer cells more efficiently. With the recent milestones achieved, PH-762 has progressed through crucial phases of clinical development, paving the way for potential market entry.Clinical Trials—A Gateway to AdvancementPhio's commitment to advancing PH-762 through rigorous clinical trials demonstrates its dedication to ensuring safety and efficacy. Clinical trials are essential in the drug development process as they scrutinize the therapeutic effects, side effects, and overall impact on patients. The ongoing trials for PH-762 will provide invaluable data that could define its future role in clinical settings.The Broader Implications for BiotechnologyThe implications of advancements like PH-762 extend beyond just Phio Pharmaceuticals. As pharmaceutical companies innovate with new therapies, they also contribute to a broader understanding of the immune system and its potential. Each successful candidate adds to the collective knowledge that can drive future research and lead to more effective treatments across a range of diseases.Cultural Shift Toward Personalized MedicineThe development of precision therapies like PH-762 is reflective of a broader trend towards personalized medicine. Unlike traditional treatments that plant a one-size-fits-all solution, targeted therapies offer the potential for tailored treatment plans, focusing on the individual characteristics of a patient's disease. This shift not only promises better outcomes but also signals an important evolution in patient care that could redefine standard practices in medicine.A Look at Future InnovationsAs Phio Pharmaceuticals continues on its path, one can only speculate about the future innovations awaiting in the biotech sector. The successful advances of PH-762 are encouraging, opening the door for new ideas, techniques, and therapies that may emerge in the coming years. This could lead to breakthroughs that drastically alter how diseases are treated, enhancing quality of life for countless individuals.Final Thoughts on PH-762's JourneyPH-762 is more than just a candidate in clinical trials; it is a representation of hope, innovation, and the relentless pursuit of solutions to complex medical issues. With its advancements, Phio Pharmaceuticals is not only setting the stage for its future but also inspiring a whole industry to push boundaries and think creatively about health and healing.

06.10.2026

Medexus Secures Groundbreaking UM171 Cell Therapy for Canadians

Update Medexus Advances Hematological Care with UM171 Cell Therapy Medexus Pharmaceuticals has made significant strides in the Canadian biotech arena by securing exclusive rights to commercialize UM171 Cell Therapy, known as Zemcelpro®. Announced on June 9, 2026, this innovative treatment, which has recently received conditional marketing authorization from the European Commission, represents a new hope for patients grappling with hematological malignancies, such as leukemias and myelodysplastic syndromes. Bridging the Gap in Hematopoietic Stem Cell Transplantation Currently, the availability of suitable stem cell donors remains a major hurdle in treating blood cancers effectively. With over 843 allogeneic hematopoietic stem cell transplantation (allo-HSCT) procedures carried out in Canada in 2024 alone, the need for alternative solutions is pressing. UM171 Cell Therapy is uniquely positioned to address this gap, as it combines UM171-expanded CD34+ cells and unexpanded CD34- cells from the same cord blood unit, maximizing therapeutic potential. Medexus's Strategic Fit in Hemato-Oncology According to Ken d'Entremont, the CEO of Medexus, this therapy aligns seamlessly with their existing product, Trecondyv® (treosulfan for injection). The addition of Zemcelpro® to their portfolio will help solidify Medexus's standing in the allo-HSCT market, enhancing the treatment landscape for Canadian patients. As the market for cell therapies evolves, Medexus aims to establish a robust framework for the future commercialization of this innovative solution. Implications of Zempalpro® on Canadian Healthcare Should Medexus receive approval for Zemcelpro® from Health Canada, it could significantly influence treatment pathways for patients who currently face limited options. The potential benefits of this therapy go beyond mere numbers; they signify a substantial shift toward personalized medicine in Canada. Challenges Ahead: Regulatory and Market Dynamics While there is optimism surrounding the commercialization of UM171 Cell Therapy, several challenges persist. For one, the product's journey toward health authority approval is still ongoing, with a full response expected only after the completion of a pivotal phase 3 clinical trial. Regulatory pathways, patient access schemes, and pricing strategies will all play critical roles in determining how quickly and effectively Zemcelpro® can enter the market. Future Directions for Zemcelpro® and Similar Innovations With the recent demand for increased access to stem cell therapy and auxiliary treatments, companies like Cordex Biologics, which developed Zemcelpro®, are looking to the future. Their goal is to initiate further international multi-center trials focusing on high-risk acute leukemias and myelodysplastic syndromes. As regulatory frameworks evolve, the landscape for treatments like UM171 Cell Therapy will likely change, opening new doors for patients. The Overall Significance: A New Hope for Patients The authorization of Zemcelpro® is more than just a commercial opportunity for Medexus; it represents a potential lifeline for thousands of Canadians affected by blood cancers. As these patients grossly underrepresented in transplant candidacies due to incompatible donors, innovations in therapies offer unprecedented hope. The infusion of creativity and scientific rigor seen in therapies like UM171 highlights the crucial need for continued investment in biotechnological advancements. With patient needs at the forefront, it is vital for stakeholders across healthcare to facilitate timely access to these essential therapies. As we await further developments, Medexus is committed to driving this innovation to fruition, ensuring that treatment options keep pace with the evolving challenges faced by patients in the field of hematology.

04.23.2026

Phio Pharmaceuticals Revolutionizes Cancer Treatment with INTASYL Technology

Update Phio Pharmaceuticals: Pioneering the Future of Cancer Treatment In the evolving landscape of cancer therapeutics, Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is emerging as a formidable player. The company's innovative approach leverages its INTASYL® gene silencing technology to combat various forms of cancer. During the upcoming Renmark Financial Communications Live Virtual Non-Deal Roadshow on April 29, 2026, CEO Robert Bitterman will delve into Phio's groundbreaking treatments, particularly focusing on their lead candidate, PH-762, which is currently under evaluation for cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma. Understanding INTASYL: A Novel Gene Silencing Technology At the heart of Phio's developments is its INTASYL® technology, which is designed to silence the PD-1 gene, a significant player in the immune response related to various cancers. This technology enhances the body's immune cells, making them more effective in targeting and eliminating cancer cells. The Phase 1b clinical trial results indicate promising potential, showing a significant pathological response rate in patients treated with PH-762. According to recent communications, out of 22 patients treated so far, a notable 65% exhibited a pathological response. Specifically, six out of seven patients in the highest dosing cohort achieved remarkable results, exhibiting an 85% pathological response, which indicates that the technology could provide a non-surgical alternative for treating skin cancers. Recent Milestones: Pathological Responses and Safety Considerations Phio’s continual updates emphasize the importance of monitoring safety alongside efficacy. As detailed in the previous reports, the comprehensive safety reviews confirmed no serious adverse effects or dose-limiting toxicities throughout the study. This finding is particularly significant as it highlights the drug's potential as a safe treatment alternative in a domain where such attributes are pivotal. Further insights into the Phase 1b trial illustrate that among the patients with cutaneous carcinomas who completed treatment, a cumulative 100% clearance was achieved in one patient, with two others displaying greater than 90% and 50% clearance rates respectively. This progress not only signifies a breakthrough in application but also positions Phio as a key player in the fight against skin cancers. Live Virtual Non-Deal Roadshow: A Platform for Visibility The upcoming presentation offers an excellent opportunity for investors and stakeholders to engage directly with Phio's leadership. Bitterman’s presentation will not only cover the clinical advancements of INTASYL but also outline the company’s strategic plans for future development. The interactive Q&A format will likely illuminate further details regarding ongoing clinical trials and overall company direction. In a field where transparency and communication regarding advancements are crucial, such public forums serve as vital conduits of information to the investor community and patients alike. Future Directions: What Lies Ahead for Phio? The presentation on April 29, 2026, could indeed provide forward-thinking observers insights into expected milestones such as the timing for FDA submissions and the next steps in clinical study designs related to PH-762. As the field of immuno-oncology continues to evolve, keeping a close watch on Phio's progression could yield insights into emergent treatment paradigms that revolutionize cancer therapy. With the ongoing development of therapeutic alternatives to traditional surgery, the advances made by Phio Pharmaceuticals warrant attention. As clinical results continue to unfold, they may pave the way for more effective, less invasive options that could ultimately change the landscape of cancer treatment. Conclusion: The Case for Continued Vigilance in Cancer Treatments The fight against cancer is multifaceted, necessitating an array of innovative solutions. Phio Pharmaceuticals signifies a beacon of hope in this landscape with its commitment to advancing its INTASYL technology and providing updated, actionable information through various channels, including the upcoming roadshow. Maintaining awareness and engagement with organizations like Phio could foster a greater understanding of the next wave of cancer therapies.

Where Conventional Meets Natural for a Healthier You

Parallel Health World News offers clarity and actionable knowledge for those eager to harmonize the best of both medical worlds, helping its audience achieve a truly integrative approach to health and wellness.

Advertise
Parallel Health World News
SeamanDan.com
Dan Seaman Media Press Pass

ABOUT US
SeamanDan LLC is a modern news media agency creating niche digital channels that inform and engage. We specialize in launching focused platforms that deliver impactful content.  Our current brands include:
Parallel Health World
AI Insights Hub
MLM News AI
Rider Safe News
Meme Crypto News
Rugged Trails Network
Recreation Wave
Outdoor Odyssey News
Eco-Innovation Hub
Metal Green Innovators
Autism Foundation News

At SeamanDan LLC, we don't just report the news we create platforms that build communities, foster trust, and drive forward-thinking conversations.  Can we build a channel for you?

© 2026 Parallel Health World News All Rights Reserved. 810 N Main St #187, Spearfish, SD 57783 . Contact Us . Terms of Service . Privacy Policy

{"company":"Parallel Health World News","address":", ,  ","city":"","state":"","zip":"","email":"seamandan@seamandan.com","tos":"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","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*